Research programme: protein degradation and immunomodulator therapy - BioTheryX

Drug Profile

Research programme: protein degradation and immunomodulator therapy - BioTheryX

Alternative Names: CKI-alpha inhibitors

Latest Information Update: 24 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer BioTheryX; Yissum Research Development Company
  • Class
  • Mechanism of Action Casein kinase I inhibitors; Casein kinase Ialpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies
  • Research Solid tumours

Most Recent Events

  • 04 May 2016 Early research in Solid tumours in USA (unspecified route) before May 2016
  • 04 May 2016 Preclinical trials in Haematological malignancies in USA (unspecified route) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top